Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 738-747

  Margolis, Jay ^a   Cao, Zhun ^a   Fowler, Robert ^a   Harnett, James ^b   Sanchez, Robert J ^b   Mardekian, Jack ^b   Silverman, Stuart L ^c  

^a THOMSON REUTERS   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetic peripheral neuropathy; Duloxetine; Neuropathic pain; Pregabalin

Indexed keywords

ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DULOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIABETIC NEUROPATHY; EMPLOYEE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PRESCRIPTION; SAMPLE SIZE; TREATMENT DURATION; WORK DISABILITY;

ADOLESCENT; ADULT; AGE FACTORS; ANALGESICS; COMORBIDITY; DIABETIC NEUROPATHIES; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PAIN; SEX FACTORS; SOCIOECONOMIC FACTORS; THIOPHENES; YOUNG ADULT;

EID: 78650066761     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.535878     Document Type: Article

References (23)

1. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-962
2. National Diabetes Statistics, 2007. From the U.S. Department of Health and Human Services, National Institutes Of Health, National Diabetes Information Clearinghouse. Website: Available at: http://diabetes.niddk.nih.gov/DM/ PUBS/statistics/DM-Statistics.pdf [Last accessed 2 February 2010]
3. Boulton AJ. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9-15
4. Hartsfield CL, Korner EJ, Ellis JL, et al. Painful diabetic peripheral neuropathy in a managed care setting: patient identification, prevalence estimates, and pharmacy utilization patterns. Popul Health Manag 2008;11:317-328
5. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132: 237-251
6. King SA. Diabetic peripheral neuropathic pain: effective management. Consultant Live 2008;48:11. Available at: http://www.consultantlive.com/display/ article/10162/1337377. [Last accessed 2 February 2010]
7. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81:S12-25
8. Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81:S3-11
9. Attal N, Cruccu G, Haanpä ä M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-1169
10. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-1534
11. Cymbalta (duloxetine) Full Prescribing Information. Eli Lilly and Company, Indianapolis, IN, January 2010
12. Argoff CE, Backonja MM, Belgrade MJ, et al. Diabetic peripheral neuropathic pain: consensus guidelines for treatment. J Fam Pract 2006;Suppl:3-19
13. Lyrica (pregabalin) Full Prescribing Information. Pfizer Inc, New York, NY, December 2009
14. Quilici S, Chancellor J, Lö thgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009;9:6
15. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-149
16. Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30:374-385
17. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med 2007;49:672-679
18. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790-1795
19. Ritzwoller DP, Ellis JL, Korner EJ, et al. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Curr Med Res Opin 2009;25:1319-1328
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55
21. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-38
22. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
23. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22